{"id":386386,"date":"2020-11-22T22:53:15","date_gmt":"2020-11-23T03:53:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386386"},"modified":"2020-11-22T22:53:15","modified_gmt":"2020-11-23T03:53:15","slug":"biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","title":{"rendered":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN"},"content":{"rendered":"

<\/p>\n

\nBIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN\n<\/p>\n

NEW ORLEANS–(BUSINESS WIRE<\/a>)–
\nClaimsFiler, a FREE shareholder information service, reminds investors that they have only untilNovember 24, 2020<\/span><\/b> to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company\u2019s securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California.\n<\/p>\n

\nGet Help\n<\/p>\n

\nBioMarin investors should visit us at https:\/\/www.claimsfiler.com\/cases\/view-biomarin-pharmaceutical-inc-securities-litigation<\/a> or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.\n<\/p>\n

\nAbout the Lawsuit\n<\/p>\n

\nBioMarin and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.\n<\/p>\n

\nThe alleged false and misleading statements and omissions include, but are not limited to, that: (i) differences between the Phase 1\/2 and Phase 3 study for its drug candidate, valoctocogene roxaparvovec, limited the reliability of the Phase 1\/2 study to support the drug\u2019s durability of effect; (ii) as a result, it was foreseeable that the FDA would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result of the foregoing, BioMarin\u2019s statements were materially false and misleading at all relevant times\n<\/p>\n

\nThe case is Tsantes v. BioMarin Pharmaceutical Inc., et al<\/i>, 20-cv-06719.\n<\/p>\n

\nAbout ClaimsFiler\n<\/p>\n

\nClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.\n<\/p>\n

\nTo learn more about ClaimsFiler, visit www.claimsfiler.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201122005064\/en\/<\/a><\/span><\/p>\n

\nClaimsFiler
\n
Lewis Kahn, 844-367-9658
\n
https:\/\/www.claimsfiler.com<\/a><\/p>\n

KEYWORDS:<\/b> Louisiana United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN NEW ORLEANS–(BUSINESS WIRE)– ClaimsFiler, a FREE shareholder information service, reminds investors that they have only untilNovember 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company\u2019s securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. Get Help BioMarin investors should visit us at https:\/\/www.claimsfiler.com\/cases\/view-biomarin-pharmaceutical-inc-securities-litigation or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss … <\/p>\n

Continue reading “BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386386","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN NEW ORLEANS–(BUSINESS WIRE)– ClaimsFiler, a FREE shareholder information service, reminds investors that they have only untilNovember 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company\u2019s securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. Get Help BioMarin investors should visit us at https:\/\/www.claimsfiler.com\/cases\/view-biomarin-pharmaceutical-inc-securities-litigation or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss … Continue reading "BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T03:53:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN\",\"datePublished\":\"2020-11-23T03:53:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"},\"wordCount\":408,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\",\"name\":\"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-23T03:53:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","og_locale":"en_US","og_type":"article","og_title":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk","og_description":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN NEW ORLEANS–(BUSINESS WIRE)– ClaimsFiler, a FREE shareholder information service, reminds investors that they have only untilNovember 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company\u2019s securities between February 28, 2020 and August 18, 2020, inclusive (the \u201cClass Period\u201d). This action is pending in the United States District Court for the Northern District of California. Get Help BioMarin investors should visit us at https:\/\/www.claimsfiler.com\/cases\/view-biomarin-pharmaceutical-inc-securities-litigation or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss … Continue reading \"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T03:53:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN","datePublished":"2020-11-23T03:53:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"},"wordCount":408,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","name":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-23T03:53:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201122005064r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarin-48-hour-deadline-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100000-of-deadline-in-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386386"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}